
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc has demonstrated strong financial performance, with a reported revenue growth of 19% year-over-year in 2024 and an anticipated 17% growth for 2025, attributing this success primarily to its testing services. The company achieved total revenue of $86.6 million in 4Q24, reflecting a 32% year-over-year increase, which surpassed projections and indicates a robust demand for its products and services. CareDx's growth strategy focuses on expanding testing volumes through a comprehensive go-to-market strategy, increased payer coverage, and operational efficiencies, positioning the company to reach its long-term revenue target of $500 million by 2027.
Bears say
CareDx Inc faces significant risks that contribute to a negative outlook for its stock, primarily stemming from potential reimbursement challenges, which could severely impact financial results if the company fails to secure adequate reimbursement for its testing services. The competitive landscape poses another threat, as the emergence of superior testing solutions from rivals could lead to a loss of market share, further jeopardizing CareDx's financial stability. Additionally, external factors such as healthcare policy changes and stringent regulations in the diagnostics industry, as well as integration risks associated with acquisitions, could adversely affect the company's financial performance and growth prospects.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares